<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="128476">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429623</url>
  </required_header>
  <id_info>
    <org_study_id>CO17730</org_study_id>
    <secondary_id>2011-004187-30</secondary_id>
    <nct_id>NCT01429623</nct_id>
  </id_info>
  <brief_title>A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)</brief_title>
  <official_title>A 36-month, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avraham Pharmaceuticals Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avraham Pharmaceuticals Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with the investigational drug
      ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive
      Impairment (MCI). MCI is now recognized as a precursor to AD and clinical tools are
      available to assess cognitive performance at this earlier stage. Ladostigil is currently
      under investigation for the treatment of AD. In this study, the investigators will be
      examining ladostigil at a lower dose level. At this dose level, ladostigil has been shown to
      reduce signs of early memory loss in animals. Thus, in this study the investigators are
      attempting to determine if earlier invention with a lower dose of ladostigil will
      significantly reduce initial memory loss and delay the subsequent progression to more
      serious cognitive dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conversion from Mild Cognitive Impairment to Alzheimer's disease compared to placebo</measure>
    <time_frame>3,6,12,18,24,30 and 36 months</time_frame>
    <description>Total number of conversions from Mild Cognitive Impairment to Alzheimer's disease across entire 3 year study period. Conversion is determined, or defined, by a Clinical Dementia Rating (CDR) score of greater than or equal to one.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Geriatric Depression Scale for ladostigil versus placebo population</measure>
    <time_frame>3,6,12,18,24,30 and 36 months</time_frame>
    <description>Mean value change (from baseline) in Geriatric Depression Scale across entire study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuropsychiatric Test Battery for ladostigil versus placebo population</measure>
    <time_frame>3,6,12,18,24,30 and 36 months</time_frame>
    <description>Mean value change (from baseline) in Neuropsychiatric Test Battery across entire study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disability Assessment in Dementia for ladostigil versus placebo population</measure>
    <time_frame>3,6,12,18,24,30 and 36 months</time_frame>
    <description>Mean value change (from baseline) in Disability Assessment in Dementia across entire study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of 10mg ladostigil versus placebo treatment.</measure>
    <time_frame>3,6,9,12,15,18,21, 24, 27, 30, 33 and 36 months</time_frame>
    <description>Clinical laboratory safety data will be collected at 3,6 12,18,24,20 and 36 months. Vital signs will be measured and adverse events (including changes to concomitant medications) will be documented at all study visits (i.e. 3,6,9,12,15,18,21,24,27,30,33 and 36 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to development of probable or possible Alzheimer's disease</measure>
    <time_frame>3, 6, 12, 18, 24, 30 and 36 months</time_frame>
    <description>Mean time to development of probable or possible Alzheimer's disease (according to NINCDS-ADRDA criteria) for ladostigil versus placebo conversion populations. Development of, or converion to, Alzheimer's disease will determined by a Clinical Dementia Rating (CDR) score of greater than or equal to one. Time to conversion from MCI to AD will be analysed by means of Kaplan Meier's survival method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>ladostigil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg ladostigil base</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>drug product excipients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ladostigil hemitartrate</intervention_name>
    <description>10mg ladostigil base administered once daily as hard gelatin capsule</description>
    <arm_group_label>ladostigil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women (non-childbearing potential) with a diagnosis of Mild Cognitive
             Impairment (MCI) according to consensus criteria as defined by Petersen

          -  Abnormal memory function will be evaluated by Verbal Paired Associates from the
             Wechsler Memory Scale - Revised. Norm values for healthy adults in two age cohorts
             are: a) 50-70 years 19.7 (SD=2.9) and b) 75-95 years 18.3 (SD=2.8). Patients that
             score &lt; or = 23 will be included.

          -  Clinical Dementia Rating (CDR) score of 0.5 (Memory box score 0.5 or 1, no box score
             &gt; 1)

          -  Mini Mental State Examination (MMSE) &gt; 24 and &lt; or = 30

          -  General cognition and functional performance is sufficiently preserved such that a
             diagnosis of AD can be excluded by the site physician at the time of the screening
             visit.

          -  No significant cerebrovascular disease indicated by Modified Hackinski Ischaemic
             Score equal to or below 4

          -  Age 55-85 years based upon correlation of cognition and Scheltens score observed in
             this age range

          -  Geriatric Depression Scale (GDS) of &lt; or = 5

          -  An informer who has frequent contact with the subject (e.g. an average of 10 hours
             per week or more) is available and agrees to monitor administration of study drug, to
             observe the subject for adverse events and to accompany the subject to clinical
             visits during the trial, if the presence of the informer is required.

          -  All patients have to undergo an MRI scan after the screening visit, i.e. during the
             screening visit, irrespective of MRIs having been performed prior to entry into the
             study. MRI findings have to be consistent with a diagnosis of MCI.

          -  Central rating of medial temporal lobe according to Scheltens scale. The right and
             left medial temporal structures will be rated separately and an overall estimate will
             be deduced using the average of the two ratings. An average score &gt; 1 is required to
             make patients eligible for the study.

          -  Adequate visual and auditory acuity must be demonstrated to allow for
             neuropsychological testing.

          -  Good general health status acceptable for participation in a 36-month clinical trial,
             with no additional diseases expected to interfere with the study

          -  ECG without clinically significant abnormalities according to exclusion criteria
             listed below

          -  Subject is not pregnant, lactating or of childbearing potential (i.e. women must be
             two years post menopausal or surgically sterile)

          -  Signed informed consent by patient and informer prior to any study specific procedure

        Exclusion Criteria:

          -  Failure to perform screening or baseline examinations

          -  Any significant neurological disease other than suspected MCI

          -  MRI exclusion criteria which allow for mild concomitant vascular lesions are:

               -  Thromboembolic infarction

               -  Other focal lesions which may be responsible for the cognitive status of the
                  patient such as infectious disease, space-occupying lesions, normal pressure
                  hydrocephalus or any other abnormalities associated with significant central
                  nervous disease

               -  More than one lacunar infarct defined as a focal lesion of CSF signal intensity
                  with a diameter of &lt; 1.5cm in any dimension

               -  Any lacunar infarct in a strategically important location such as the thalamus,
                  hippocampus of either hemisphere, head of the left caudate

               -  White matter lesions involving more than 25% of the hemispheric white matter

               -  Implants such as pacemakers, insulin pumps, cochlear implants, nerve
                  stimulators, implantable cardioverter defibrillators, and other medical implants
                  that have not been certified for MRI

               -  Ferromagnetic foreign bodies such as shell fragments need to be considered on an
                  individual basis

               -  Metallic implants that can cause artifacts and RF induced heating such as
                  surgical prostheses or aneurysm clips need to be considered on an individual
                  basis

          -  Clinical or laboratory findings consistent with:

               -  Central nervous system diseases such as those resulting from severe head trauma,
                  tumours, subdural haematomas or other space occupying processes, etc

               -  Seizure disorder

               -  Other infectious, metabolic or systemic diseases affecting central nervous
                  system (syphilis, present hypothyroidism, present vitamin B12 or folate
                  deficiency, serum electrolytes out of normal range, juvenile onset diabetes
                  mellitus, etc)

          -  History or evidence of schizophrenia or bipolar disorder (DSM IV criteria); active
             major depression

          -  Clinically significant advanced or unstable disease that may interfere with primary
             or secondary variable evaluations, and which may bias the assessment of the clinical
             or mental status of the patient or put the patient at special risk, such as:

               -  Malignant tumours within the last five years except skin malignancies (other
                  than melanoma) or indolent prostate cancer

               -  Metastases

               -  History of myocardial infarction within one year prior to screening or unstable
                  or severe cardiovascular disease including angina or congestive heart failure
                  with symptoms at rest

               -  Uncontrolled hypertension (systolic pressure &gt; 170mmHg or diastolic pressure &gt;
                  100mmHg)

               -  Bradycardia (persistent heart beat &lt; 50/min) or tachycardia ( persistent heart
                  beat &gt; 100/min)

               -  AV block (type II / Mobitz II and type III), congenital long QT syndrome, sinus
                  node dysfunction or prolonged QTcB-interval (males &gt; 450msec, females &gt; 470msec)

               -  Clinically significant obstructive pulmonary disease or asthma

               -  Clinically significant laboratory findings that indicate abnormalities in blood
                  biochemistry, blood haematology or urinalysis

               -  Uncontrolled diabetes mellitus defined by HbA1c &gt; 8.5

               -  Clinically significant liver disease, coagulopathy or vitamin K deficiency
                  within the past two years prior to screening

               -  Renal insufficiency (serum creatinine &gt; mg/dl or creatinine clearance &lt; or = to
                  45ml/min according to Cockgroft-Gault formula); in case of creatinine clearance
                  &lt; or = 45ml/min, an alternative verification of the renal function must be
                  completed using cystatin C analysis. In case of normal level of cystatin C, the
                  patient can be included in the study.

          -  Any prior use of medications approved by local authorities for the treatment of
             Alzheimer's disease (e.g. tacrine, donepezil, rivastigmine, galantamine, memantine or
             other newly approved medications)

          -  Disability that may prevent the subject from completing all study requirements (e.g.
             blindness, deafness, severe language difficulty, etc)

          -  Women who are fertile and of child bearing potential

          -  Chronic daily intake of antidepressants as noted in section 9.5 of the clinical study
             protocol

          -  Suspected or known drug or alcohol abuse, i.e. more than approximately 60g alcohol
             (approximately 1 lter of beer or 0.5 liter of wine) per day as indicated by elevated
             MCV significantly above normal value at screening

          -  Suspected or known allergy to any components of the study treatments

          -  Enrollment in another investigational study or intake of investigational drug within
             the previous three months

          -  Any condition (e.g. epilepsy) which in the opinion of the investigator makes the
             patient unsuitable for inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tzvi Dwolatzky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Department of Geriatrics and Memory Clinic, Mental Health Center, Israel P.O. Box 4600, Beersheva 84170</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universitat Graz, Abteilung fur Neurologie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Hall, Memory Klinik</name>
      <address>
        <city>Hall in Tirol</city>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatordination Rainer</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienambulanz St. Joseph Krankenhaus Berlin, Emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>13088</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke-Universitat, Universitatsklinik fur Neurologie und fur Stereotaktische</name>
      <address>
        <city>Magdeburg</city>
        <zip>30120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Nordwest</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Geriatrics and Memory Clinic, Mental Health Center, Israel</name>
      <address>
        <city>Beersheva</city>
        <zip>84170</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive Neurology Unit, Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive Clinic, Department of Geriatrics, Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Physical Medicine and Rehabilitation, Hadassah University Hospital, PO Box 24035</name>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memory Clinic, Sheba Medical Center at Tel Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Memory and Attention Disorders, Department of Neurology, Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, BÃ¤ckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004 Sep;256(3):240-6. Review.</citation>
    <PMID>15324367</PMID>
  </reference>
  <reference>
    <citation>DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, Thal LJ, Jin S, Jack CR Jr, Scheltens P; Alzheimer's Disease Cooperative Study Group.. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol. 2007 Jan;64(1):108-15. Erratum in: Arch Neurol. 2007 Mar;64(3):459.</citation>
    <PMID>17210817</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 22, 2013</lastchanged_date>
  <firstreceived_date>September 3, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Early Stage Dementia</keyword>
  <keyword>Conversion to Alzheimer's disease</keyword>
  <keyword>Memory Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Mild Cognitive Impairment</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
